Potential role of 68Ga- and 177Lu-cyclic pentapeptides for in-vivo targeting CXCR4 receptor expression in chemotherapy relapse MCL patient.

PubMed 2026 Open access

Read full text
Authors: Tamanna Lakhanpal, Bhagwant Rai Mittal, Jaya Shukla, Y. Rathore, Rajender Kumar, Harmandeep Singh, Nivedita Rana
DOI: 10.22038/aojnmb.2025.85362.1615
Cited by: 0

Abstract

Objectives: Lu-cyclic pentapeptides was developed to in-vivo target the CXCR4 receptor expression. Methods: Ga-cyclic pentapeptide was performed to check the in-vivo CXCR4 expression in chemotherapy relapse MCL patient. Dosimetry studies in the same patient was performed with different time-point imaging to calculate the residence time and predict the critical organ. Results: Lu-cyclic pentapeptide indicated kidneys as the critical organ with max residence time of 5.39 h. Conclusion: Lu- cyclic pentapeptides have the potential to in-vivo target the CXCR4 receptor expression.

Fields of Study & Subjects

Chemokine receptors and signaling Lymphoma Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications

Publication details

Journal / source
PubMed
Volume
14
Issue
1
Pages
117–121
Publication date
1 January 2026
Language
EN